D-0079-2022 Class III Terminated

Recalled by MACLEODS PHARMA USA, INC — Princeton, NJ

FDA drug recall D-0079-2022 was initiated by MACLEODS PHARMA USA, INC on Oct 18, 2021 and is designated Class III. Reason for recall: Out-of-specification test results obtained in Organic Impurities test during analysis of controlled samples. The recall status is terminated (terminated Apr 24, 2024). Affected quantity: 13,260 Blister Packs/238,680 tablets.

Recall details

Product Type
Drugs
Report Date
Nov 3, 2021
Initiation Date
Oct 18, 2021
Termination Date
Apr 24, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
13,260 Blister Packs/238,680 tablets

Product description

Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, 12 Tablets (2 x 6 Unit-Dose Tablets) Blister Packs, Rx only, Manufactured for: Macleods Pharma USA Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, INDIA, NDC 33342-093-41

Reason for recall

Out-of-specification test results obtained in Organic Impurities test during analysis of controlled samples.

Distribution pattern

Nationwide within the United States

Code information

Lot #: BRL2102A, BRL2103A, exp. date 04/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0079-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0079-2022. Report a data issue: hello@regdatalab.com.